Allarity Therapeutics Files Q2 2024 10-Q

TL;DR

Allarity Therapeutics filed its Q2 10-Q. Financials and operations update.

AI Summary

Allarity Therapeutics, Inc. filed its 10-Q for the quarterly period ended June 30, 2024. The company, incorporated in Delaware, is based in Boston, MA, and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located at 24 School Street, 2nd Floor, Boston, MA 02108, with a contact phone number of (401) 426-4664.

Why It Matters

This filing provides investors and stakeholders with the latest financial and operational details for Allarity Therapeutics, Inc. as of June 30, 2024.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Allarity Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 001-41160 — Commission File Number (Identifies the company's filing with the SEC.)
• 20240630 — Quarterly Period End Date (Specifies the end of the reporting period for this 10-Q.)

Key Players & Entities

• Allarity Therapeutics, Inc. (company) — Registrant
• June 30, 2024 (date) — Quarterly period end date
• 24 School Street, 2nd Floor, Boston, MA 02108 (location) — Principal executive offices address
• 001-41160 (identifier) — Commission File Number
• 2834 (identifier) — Standard Industrial Classification (Pharmaceutical Preparations)

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Market
• $0 — he registrant's common stock, par value $0.0001, outstanding. Table of Contents

Filing Documents

• ea0210398-10q_allarity.htm (10-Q) — 1074KB
• ea021039801ex31-1_allarity.htm (EX-31.1) — 10KB
• ea021039801ex31-2_allarity.htm (EX-31.2) — 10KB
• ea021039801ex32-1_allarity.htm (EX-32.1) — 4KB
• ea021039801ex32-2_allarity.htm (EX-32.2) — 4KB
• 0001213900-24-065252.txt ( ) — 6237KB
• allr-20240630.xsd (EX-101.SCH) — 64KB
• allr-20240630_cal.xml (EX-101.CAL) — 34KB
• allr-20240630_def.xml (EX-101.DEF) — 304KB
• allr-20240630_lab.xml (EX-101.LAB) — 519KB
• allr-20240630_pre.xml (EX-101.PRE) — 305KB
• ea0210398-10q_allarity_htm.xml (XML) — 761KB

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 30 Item 4. Controls and Procedures 30 PART II—OTHER INFORMATION 31 Item 1. Legal Proceedings 31 Item 1A. Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 31 Item 3. Defaults Upon Senior Securities 31 Item 4. Mine Safety Disclosures 31 Item 5. Other Information 31 Item 6. Exhibits 32

Signatures

Signatures 33 i Unless the context indicates otherwise, references in this Quarterly Report on Form 10-Q (the "Quarterly Report") to the "Company," "Allarity," "we," "us," "our" and similar terms refer to Allarity Therapeutics, Inc., Allarity Therapeutics A/S (as predecessor) and its respective consolidated subsidiaries. On April 9, 2024, we effected a 1-for-20 reverse stock split of the shares of our Common Stock (the "Reverse Stock Split"). All historical share and per share amounts reflected throughout this Quarterly Report have been adjusted to reflect the Reverse Stock Split. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report contains statements we believe are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Those forward-looking statements are intended to enjoy the protection of the safe harbor for forward-looking "aim," "ambitions," "anticipate," "believe," "committed," "continue," "could," "designed," "estimate," "expect," "forecast," "future," "goals," "grow," "guidance," "intend," "likely," "may," "milestone," "objective," "on track," "opportunity," "outlook," "pending," "plan," "position," "possible," "potential," "predict," "progress," "roadmap," "seek," "should," "strive," "targets," "to be," "upcoming," "will," "would," and variations of such words and similar expressions identify forward-looking statements, which are not historical in nature. Forward-looking statements may appear throughout this Quarterly Report and other documents we file with the Securities and Exchange Commission (the "SEC"). Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated by these forward-looking statements. These risks and uncertainties include, but are not limited to, the fa

financial statements include the accounts of the Company and its wholly owned subsidiaries

financial statements include the accounts of the Company and its wholly owned subsidiaries: Name Country of Incorporation Allarity Acquisition Subsidiary Inc. United States Allarity Therapeutics Europe ApS (formerly Oncology Venture Product Development ApS)* Denmark Allarity Therapeutics Denmark ApS (formerly OV-SPV2 ApS)* Denmark MPI Inc.* (1) United States * Wholly-owned subsidiary of Allarity Acquisition Subsidiary, Inc. (1) In the process of being dissolved because inactive. All intercompany transactions and balances, including unrealized profits from intercompany sales, have been eliminated upon consolidation. (b) Foreign currency and currency translation The functional currency is the currency of the primary economic environment in which an entity's operations are conducted. The Company and its subsidiaries operate mainly in Denmark and the United States. The functional currencies of the Company's subsidiaries are their local currency. The Company's reporting currency is the U.S. dollar. The Company translates the assets and liabilities of its Denmark subsidiaries into the U.S. dollar at the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during each monthly period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the condensed consolidated statements of changes in stockholders' equity (deficit) as a component of accumulated other comprehensive loss. Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are re-measured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included

View Full Filing

View this 10-Q filing on SEC EDGAR